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Abstract
We investigated the incidence, clinical characteristics, risk factors, and outcome of meningoencephalitis (ME) in patients with
COVID-19 attending emergency departments (ED), before hospitalization. We retrospectively reviewed all COVID patients
diagnosed with ME in 61 Spanish EDs (20% of Spanish EDs, COVID-ME) during the COVID pandemic. We formed two
control groups: non-COVID patients with ME (non-COVID-ME) and COVID patients without ME (COVID-non-ME).
Unadjusted comparisons between cases and controls were performed regarding 57 baseline and clinical characteristics and 4
outcomes. Cerebrospinal fluid (CSF) biochemical and serologic findings of COVID-ME and non-COVID-ME were also inves-
tigated.We identified 29ME in 71,904 patients with COVID-19 attending EDs (0.40‰, 95%CI=0.27–0.58). This incidence was
higher than that observed in non-COVID patients (150/1,358,134, 0.11‰, 95%CI=0.09–0.13; OR=3.65, 95%CI=2.45–5.44).
With respect to non-COVID-ME, COVID-ME more frequently had dyspnea and chest X-ray abnormalities, and neck stiffness
was less frequent (OR=0.3, 95%CI=0.1–0.9). In 69.0% of COVID-ME, CSF cells were predominantly lymphocytes, and SARS-
CoV-2 antigen was detected byRT-PCR in 1 patient. The clinical characteristics associatedwith a higher risk of presentingME in
COVID patients were vomiting (OR=3.7, 95%CI=1.4–10.2), headache (OR=24.7, 95%CI=10.2–60.1), and altered mental status
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(OR=12.9, 95%CI=6.6–25.0). COVID-ME patients had a higher in-hospital mortality than non-COVID-ME patients (OR=2.26;
95%CI=1.04–4.48), and a higher need for hospitalization (OR=8.02; 95%CI=1.19–66.7) and intensive care admission
(OR=5.89; 95%CI=3.12–11.14) than COVID-non-ME patients. ME is an unusual form of COVID presentation (<0.5‰ cases),
but is more than 4-fold more frequent than in non-COVID patients attending the ED. As the majority of these MEs had
lymphocytic predominance and in one patient SARS-CoV-2 antigen was detected in CSF, SARS-CoV-2 could be the cause
of most of the cases observed. COVID-ME patients had a higher unadjusted in-hospital mortality than non-COVID-ME patients.
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Introduction
Coronavirus disease 2019 (COVID-19), caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is
predominantly characterized by lower respiratory tract and
cardiovascular system involvement. However, possible neu-
rological symptoms have been described, such as headache,
dizziness, hypogeusia, or neuralgia, even in up to 36.4% of the
patients [1]. Nevertheless, the symptoms described are com-
mon in many infections and could represent disturbances in
neurological function rather than neurological disease.
Anosmia and ageusia have received much attention, but are
ubiquitous in other common upper respiratory tract infections
[2]. Some neurological complications of COVID-19, includ-
ing meningoencephalitis (ME), have been previously de-
scribed as case reports [3–5].
Connections between viral infections and central nervous
system (CNS) pathologies are not new. Coronaviruses are not
a common cause of neurological disease, but members of
coronaviridae have already demonstrated the ability to pro-
duce neurological symptoms, including brain inflammation
and encephalomyelitis, as well as presumed parainfectious
disorders [2, 6–9]. Detection of SARS-CoV RNA in the
CSF of a patient with SARS has been reported [10].
However, the pathophysiological mechanism of illness and
the relationship between COVID-19 and CNS involvement
remain unclear. The relative expression of the two key co-
receptors for SARS-CoV-2 entry, ACE2, and TMPRSS2 has
been described across multiple tissues and highlights that
there is minimal expression in brain tissue, suggesting that
direct brain infection would not be a common phenomenon.
The one brain cell type, which does express both genes, is the
oligodendrocyte, and therefore, SARS-CoV-2 encephalitis,
when present, might be expected to be a predominantly white
matter disease [2]. Experimental and clinical studies
suggest brainstem involvement and the potential for
transneuronal virus transmission in addition to
misdirected host immune responses [11].
The real incidence of ME in patients with COVID-19 is
currently unknown. There are some sporadically reported
cases in patients with COVID-19 [3–5]. In order to further
investigate these aspects, we designed the present study with
the following specific objectives: (1) to determine the
frequency of ME patients with COVID-19; (2) to describe
whether there is any distinctive clinical characteristic in these
patients in comparison with ME observed in non-COVID pa-
tients; (3) to uncover risk factors associated with the develop-
ment of ME in patients with COVID-19; and (4) to investigate
the outcomes of COVID patients presenting ME.
Methods
Study design and setting
The present study forms part of the Unusual Manifestations of
Covid-19 (UMC-19) project, which was designed to investi-
gate the potential relationship between COVID-19 and 10
different entities that could be influenced by SARS-Cov-2
infection itself: Guillain-Barre syndrome, spontaneous pneu-
mothorax, acute pancreatitis, meningoencephalitis,
(myo)pericarditis, acute coronary syndrome, deep venous
thrombosis, pulmonary embolism, ictus, and gastrointestinal
bleeding. The main objectives of the UMC-19 project were
common for all entities, and consisted in the description of
incidence, risk factors, clinical characteristics, and outcomes
for each particular entity, using as comparators COVID pa-
tients that did not develop this entity as well as non-COVID
patients that did present the entity. Details of the project have
been extensively presented elsewhere [12].
In Spain, the first case of SARS-Cov-2 infection was de-
tected on January 31st, 2020, and, accordingly, the definition
of the COVID period for patient inclusion in the present study
was set from March 1st to April 30th, 2020 [13]. During this
61-day period, 213,435 cases of COVID-19 were confirmed
in Spain by the Ministry of Health [14]. For the recruitment of
controls, the UMC-19 project selected patients from two dif-
ferent periods: one corresponding to the same dates as the
cases (from March 1st to April 30th, 2020) and one corre-
sponding to same period of the previous year (from
March 1st to April 30th, 2019).
The investigators of the UMC-19 project initially contacted
152 Spanish EDs, which roughly constitute half of the 312
hospital EDs of the Spanish public health network. Of these,
81 were interested in participating and analyzed the protocol,
and finally 61 (20% of Spanish EDs) consented to participate
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and sent all the required data in due time (Fig. 1). Altogether
these 61 hospitals provide health coverage to 15.2 million
citizens (32% of the population of 46.9 million of Spain)
and make up a balanced representation of the Spanish territory
(representing 12 of the 17 Spanish autonomous communities),
type of hospital (community, reference, and high-technology
university hospitals were included), and involvement in
pandemic (with EDs attending from 1 to 47% of the ED
census during the COVID outbreak period correspond-
ing to COVID patients) [12].
The investigation of ME in COVID patients, one of the
entities included in the UMC-19 project, was labeled as
UMC-19 Study 3 (UMC-19-S3) and consisted in a retrospec-
tive, multicenter, case-control study that reviewed the medical
reports of COVID patients who attended at Spanish EDs and
who were diagnosed as havingME during ED assessment and
management, before hospitalization.
Cases of the UMC-19-S3
The case group was formed by COVID patients diagnosed
with ME made on the basis of clinical presentation, lumbar
puncture, abnormality on electroencephalography, and CT
scan. All meningoencephalitis cases fulfill the consensus def-
inition of encephalitis by the International Encephalitis
Consortium [15], and other etiologies were rule out. As we
wanted to investigate the role of SARS-CoV-19 in such un-
usual manifestations, before the patient was hospitalized and
treatment with specific drugs had been initiated, the possible
meningoencephalitis cases diagnosed during hospitalization
were excluded. On the other hand, due to the shortage in all
kind of diagnostic tests during the pandemic outbreak, diag-
nosis of COVID was accepted based on SARS-Cov-2 RNA
detection in a nasopharyngeal swab by reverse transcriptase
polymerase chain reaction (RT-PCR), a clinically compatible
clinical picture, or the presence of the typical lung parenchy-
mal infiltrates in chest X-ray or pulmonary CT in patients with
some clinical symptoms attributable to COVID. Diagnostic
adjudication was made by the principal investigator of each
center, without external review.
Controls of the UMC-19-S3
We defined two different control groups. One group was
formed by all non-COVID patients with a diagnosis of ME
attending the ED during the same period as the cases
(March 1st to April 30th, 2020), which was defined in the same
terms as cases. In order to avoid that some of these control
cases could eventually have inadvertent infection by SARS-
Cov-2, in this group, we also included all patients with ME
diagnosed in the ED fromMarch 1st to April 30th, 2019, just 1
year before the COVID pandemic. This group, named non-
Fig. 1 Study design and inclusion
flow chart
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COVID-ME (control group A), was specifically designed to
uncover the particular distinctive clinical characteristics of
ME developed in COVID patients with respect to ME devel-
oped in the general population.
The second control group was formed by COVID
patients (without ME) attending the ED during the same
period of the COVID outbreak used for case inclusion
(March 1st to April 30th, 2020). This group was formed
by selecting 10 COVID patients for every case detected
by each center. Selection was randomly performed by
the inclusion of the 5+5 COVID patients seen immedi-
ately before and after each case included by the center.
This group, named COVID-non-ME (control group B),
was specifically designed to determine the risk factors
for ME development in COVID patients.
Independent variables
We collected 57 independent variables, which included
2 demographic data (age, sex), 12 comorbidities (chron-
ic obstructive pulmonary disease, asthma, active smoker,
hypertension, dyslipidemia, diabetes mellitus, coronary
artery disease, obesity—clinically estimated, cerebrovas-
cular disease, chronic kidney disease—creatinine >2 mg/
dL, dementia, active cancer), 26 signs and symptoms
recorded at ED arrival (time elapsed since symptoms
started to ED attendance, fever, rhinorrhea, cough, ex-
pectoration, dyspnea, chest pain, abdominal pain,
vomiting, diarrhea, altered mental status, headache, an-
osmia, dysgeusia, meningeal signs (neck stiffness,
Kernig’s sign, and Brudzinski’s sign), Glasgow coma
scale, temperature, systolic blood pressure, heart rate,
respiratory rate, room air pulsioxymetry, ronchus, whis-
tles, rales), 13 laboratory parameters (C-reactive protein
(CRP), creatinine, sodium, potassium, aspartate amino
transferase (AST), bilirubin, lactate dehydrogenase
(LDH), procalcitonin, hemoglobin, leucocytes, lympho-
cytes, platelets, D-dimer), and 4 radiological findings in
chest X-ray (cardiomegaly, lung interstitial infiltrates,
ground-glass opacities, and pleural effusion). For the
cases and control group A patients, we also reviewed
data from cerebrospinal fluid (CSF) analysis, including
glucose, proteins, cells, and microbiological results.
Outcomes
We defined 4 different outcomes for cases and controls
consisting in (1) the need for hospitalization; (2) the need to
be admitted to an intensive care unit (ICU); (3) prolonged
hospitalization (defined as a length of stay >7 days, which is
the median length of stay of hospitalized patients in Spain);
and (4) in-hospital all-cause mortality.
Statistical analysis
Discrete variables were expressed as absolute values and per-
centages, and continuous variables as mean and standard de-
viation (SD) or median and interquartile range (IQR) if not
normally distributed. Incidences were expressed as cases per
thousand patients (‰) with 95% confidence interval (CI).
Differences between case group and controls groups were
assessed by the chi-square test (or Fisher exact test if needed)
for qualitative variables, and Student’s t test (or the Mann-
Whitney non-parametric test if non-normally distributed) for
quantitative variables. The magnitude of associations was
expressed as unadjusted odds ratio (OR) with 95%CI (for
continuous variables, associations were dichotomized using
clinically meaningful cutoffs). As the number of cases expect-
ed to be identified was not large, we did not plan to go further
in the investigation of the significant relationships identified in
the unadjusted analysis by using adjusted models.
In all comparisons, statistical significance was accept-
ed if the p value was < 0.05 or if 95%CI of the risk
estimations excluded the value 1. The analyses were
performed with the SPSS (v.24) statistical software
package (IBM, Armonk, NY, USA).
Ethics
The UMC-19 project was approved by the Ethics Committee
of the Hospital Clínic of Barcelona (Spain), with the reference
number HCB/2020/0534, that acted as the central ethical com-
mittee. Under the exceptional circumstances generated by the
COVID-19, the urgent need to obtain feasible data related to
this new disease, and the non-interventional and retrospective
nature of the project, obtainment of written permission from
patients to be included in the study was waived. All the pa-
tients were codified by investigators of the participating cen-
ters before their data were entered into the general database, as
patient identity remained anonymous for investigators who
analyzed the database. The UMC-19-S3 was carried out in
strict compliance with the Declaration of Helsinki principles.
The authors designed the study, gathered and analyzed the
data, vouched for the data and analysis, wrote the paper, and
decided to publish.
Results
EDs attended 486,833 patients (average of 131 patients/day/
ED), and 71,904 (14.8%) were diagnosed with COVID-19.
On the other hand, during the pre-COVID phase of the study,
943,205 patients were seen in the ED (average of 253 patients/
day/ED). Patient inclusion in each group is presented in Fig. 1.
We identified 29 ME in COVID patients (frequency=0.40‰,
95%CI=0.27–0.58), and these individuals constituted the case
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group. Among the remaining 1,358,134 non-COVID patients
attended in EDs, 150 were diagnosed as having ME (frequen-
cy=0.11‰, 95%CI=0.09–0.13). These patients constituted
control group A (non-COVID-ME). In comparison to non-
COVID patients coming to the ED, COVID patients exhibited
a significantly higher frequency of ME (OR=3.65,
95%CI=2.45–5.44). On the other hand, control group B was
made up of 290 randomly selected COVID patients without
ME (COVID-non-ME) during the same period. Infection by
SARS-CoV-2 was confirmed by RT-PCR in 48.3% and
74.8% of patients in the case group and control group B,
respectively (p=0.002). Regarding the diagnosis of COVID
patients in the COVID-ME patients with a negative RT-PCR
result, this was based on the presence of respiratory symptoms
with interstitial lung infiltrates or ground-glass lung opacities
in the X-ray or pulmonary CT.
The mean age of the case group was 57.0 (SD 23.1) years
and 17 (58.6) were female. The remaining baseline character-
istics of these patients are shown in Table 1. Compared to non-
COVID-ME, case group patients more frequently had dys-
pnea and chest X-ray abnormalities (Tables 1, 2, 3, and 4).
Neck stiffness was less frequent in COVID-ME patients that
in non-COVID-ME. From the analytical point of view,
COVID-ME patients more frequently had increased in CRP,
LDH, and D-dimer levels, and decreased leucocyte and lym-
phocyte counts. The biochemistry and cell pattern of CFS are
described in Table 3, being similar in both groups. Regarding
microbiological findings in the CFS, it should be highlighted
that after cultures, antigen testing, and multiplex PCR, no
microbiological diagnosis was achieved in patients with
COVID infection, except one patient who was RT-PCR pos-
itive for SARS-CoV-2 in CSF (Table 3).
When we compared cases with control group B patients,
we observed that headache (OR 24.7, 95%CI 10.165–60.149),
altered mental status (OR 12.864, 95%CI 6.615–25.016),
neck stiffness (OR 12.154, 95%CI 8.410–17.564), and
vomiting (OR 3.7, 95%CI 1.353–10.234) were associated
with a higher risk of ME in COVID patients. Respiratory
symptoms were more frequent in COVID-non-ME patients
than in COVID-ME patients (Tables 1, 2, 3, and 4).
Comparing the case group with control group A, the need
for hospitalization was present in 28 (96.6%) COVID-ME
patients and in 148 (98.7%) non-COVID-ME patients
(p=0.417), while admission to the ICU occurred in 12
(42.9%) COVID-ME patients and in 39 (26.4%) non-
COVID-ME patients (p=0.077). In addition, hospitalization
longer than 7 days was observed in 13 (44.8%) COVID-ME
patients and in 53 (35.3%) non-COVID-ME patients
Table 1 Baseline characteristics of patients with COVID-19 with meningoencephalitis and comparison with patients without COVID-19 with









p value1 p value2
Demographics
Age (years) [median (IQR)] 63 (39–75) 54 (32–73) 64 (51–77) 0.235 0.329
Sex (female) 17 (58.6) 66 (44.0) 136 (46.9) 0.214 0.248
Comorbidities
Hypertension 13 (44.8) 58 (38.7) 135 (46.6) 0.535 0.859
Dyslipidemia 11 (37.9) 42 (28.0) 97 (33.4) 0.284 0.627
Diabetes mellitus 6 (20.7) 37 (24.7) 52 (17.9) 0.646 0.713
Active smoker 4 (13.8) 29 (19.3) 20 (6.9) 0.460 0.355
Asthma 3 (10.3) 7 (4.7) 20 (6.9) 0.223 0.494
Coronary artery disease 2 (6.9) 7 (4.7) 22 (7.6) 0.615 0.893
Obesity (clinically estimated) 2 (6.9) 21 (14.0) 45 (15.5) 0.295 0.212
Chronic kidney disease 2 (6.9) 5 (3.3) 19 (6.6) 0.365 0.943
Immunosuppression 2 (6.9) 7 (4.7) 14 (4.8) 0.615 0.626
Cerebrovascular disease 1 (3.4) 12 (8.0) 20 (6.9) 0.387 0.475
Dementia 1 (3.4) 7 (4.7) 25 (8.6) 0.771 0.332
Active cancer 1 (3.4) 16 (10.7) 27 (9.3) 0.225 0.287
Chronic obstructive pulmonary disease 0 (0) 8 (5.3) 26 (9.0) 0.203 0.092
1 p values refer to comparison between cases and control group A
2 p values refer to comparison between cases and control group B
ME, meningoencephalitis; IQR, interquartile range
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(p=0.332). There were 7 (24.1%) deaths in the COVID-ME
patients while there were 16 (10.7%) in non-COVID-ME pa-
tients (p=0.047). Regarding comparison of the case group
with control group B, the need for hospitalization was present
in 28 (96.6%) COVID-ME patients and in 220 (75.9%)
COVID-non-ME patients (p=0.011), while admission to an
ICU was observed in 12 (42.9%) COVID-ME patients and
in 16 (7.3%) COVID-non-ME patients (p<0.001).
Hospitalization longer than 7 days was shown in 13 (44.8%)
COVID-ME patients and in 80 (27.6%) COVID-non-ME
Table 2 Clinical and analytical characteristics of the acute episode of patients with COVID-19 with meningoencephalitis and comparison with patients










p value1 p value2
Symptoms at ED arrival
Lasting symptoms (days) [median (IQR)] 3 (17) 2 (1–6) 7 (4–10) 0.183 0.003
Fever 18 (62.1) 80 (53.3) 163 (56.2) 0.387 0.544
Rhinorrhea 1 (3.4) 9 (6.0) 20 (6.6) 0.584 0.475
Cough 3 (10.3) 5 (3.3) 171 (59.0) 0.094 <0.001
Expectoration 1 (3.4) 12 (8.0) 42 (14.5) 0.387 0.097
Dyspnea 7 (24.1) 5 (3.3) 166 (57.2) <0.001 0.001
Chest pain 3 (10.3) 5 (3.3) 38 (13.1) 0.094 0.672
Abdominal pain 3 (10.3) 5 (3.3) 16 (5.5) 0.094 0.295
Vomiting 6 (20.7) 40 (26.7) 19 (6.6) 0.500 0.007
Diarrhea 3 (10.3) 12 (8.0) 50 (17.2) 0.677 0.341
Altered mental status 18 (62.1) 85 (56.7) 18 (6.2) 0.590 <0.001
Headache 12 (41.4) 86 (57.3) 35 (12.1) 0.114 <0.001
Anosmia 1 (3.4) 0 (0) 21 (7.2) 0.023 0.442
Dysgeusia 0 (0) 1 (0.7) 22 (7.6) 0.659 0.124
Seizure 4 ((13.8) 17 (11.3) 0 (0) 0.706 <0.001
Neck stiffness 3 (10.3) 49 (32.7) 0 (0) 0.015 <0.001
Kernig’s sign 1 (3.4) 23 (15.3) 0 (0) 0.086 0.002
Brudzinski’s sign 1 (3.4) 24 (16.0) 0 (0) 0.074 0.002
Signs at ED arrival [median (IQR)]
Temperature (°C) 37.3 (36.4–37.7) 37.2 (36.2–38.0) 36.6 (36.0–37.3) 0.822 0.010
SBP (mmHg) 125 (102–143) 131 (114–151) 126 (113–140) 0.142 0.551
Heart rate (bpm) 100 (80–109) 90 (78–108) 88 (78–100) 0.387 0.043
Respiratory rate (bpm) 18 (16–21) 16 (14–20) 18 (16–23) 0.017 0.955
Room air pulsioxymetry (%) 96 (91–98) 98 (95–99) 96 (93–98) 0.032 0.724
Laboratory findings [median (IQR)]
C-reactive protein (mg/dL) 4.0 (1.6–10.9) 1.6 (0.4–6.5) 5.9 (1.9–12.0) 0.045 0.468
Creatinine (mg/dL) 0.8 (0.7–1.0) 0.8 (0.6–1.0) 0.9 (0.7–1.1) 0.414 0.260
Sodium (mmol/L) 138 (134–140) 138 (135–140) 138 (136–140) 0.784 0.422
Potassium (mmol/L) 3.8 (3.6–4.2) 4.0 (3.7–4.4) 4.0 (3.7–4.4) 0.118 0.044
Aspartate amino transferase (IU/L) 26 (17–44) 24 (17–36) 30 (22–45) 0.425 0.203
Bilirubin (mg/dL) 0.7 (0.4–1.0) 0.5 (0.4–0.9) 0.5 (0.4–0.7) 0.903 0.218
Lactate dehydrogenase (IU/L) 275 (198–483) 207 (158–263) 270 (205–346) 0.020 0.574
Procalcitonin (ng/mL) 0.16 (0.11–1.06) 0.12 (0.06–1.3) 0.10 (0.05–0.18) 0.457 0.028
Hemoglobin (g/L) 13 (12–15) 13 (12–15) 13.8 (12.6–14.8) 0.968 0.921
Leucocytes count (cells/μL) 8.7 (5.0–11.8) 10.6 (7.8–14.6) 6.6 (4.9–9.1) 0.008 0.191
Lymphocytes 1.05 (0.70–1.67) 1.4 (1.0–2.3) 1.1 (0.8–1.6) 0.018 0.550
Platelets (cells/μL) 203 (144–310) 235 (182–296) 212 (164–263) 0.274 0.932
D–dimer (ng/mL) 898 (570–2770) 622 (366–1596)) 620 (360–1272) 0.138 0.036
Chest X-ray
Chest X-ray performed 25 (86.2) 118 (78.7) 280 (96.6) 0.354 0.010
Cardiomegaly 1 (4.0) 16 (14.8) 28 (10.4) 0.114 0.304
Interstitial lung infiltrates 11 (44.0) 7 (6.0) 113 (40.4) <0.001 0.772
Ground-glass lung opacities 10 (40.0) 5 (4.3) 160 (57.1) <0.001 0.098
Pleural effusion 2 (8.0) 3 (2.7) 12 (4.4) 0.208 0.415
1 p values refer to comparison between cases and control group A
2 p values refer to comparison between cases and control group B
ME, meningoencephalitis; IQR, interquartile range; SBP, systolic blood pressure; ED, emergency department
p values in bold denote statistically significant differences (p<0.05)
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patients (p=0.051), and there were 7 (24.1%) deaths among
COVID-ME patients compared to 48 (16.6%) in COVID-
non-ME patients (p=0.302). Nonetheless, we only detected
statistically significant differences in case outcomes with
respect to in-hospital mortality, which was higher than in
non-COVID-ME patients (OR=2.158; 95%CI=1.041–
4.475). There were also statistically significant differences in
the need for hospitalization (OR=8.016; 95%CI=1.190–
Table 3 Lumbar puncture and
microbiological results of patients
with COVID-19 with
meningoencephalitis and













Decreased CSF pressure (<10 H2O cm) 1 (3.4) 12 (8.0) 0.711
Increased CSF pressure (>20 H2O cm) 1 (3.4) 4 (2.7) 0.508
Glucorachia [median (IQR)] 67 (52–84) 63 (48–83) 0.306
Proteinorachia [median (IQR)] 76 (44–106) 70 (40–132) 0.786
Nucleated cells [median (IQR)] 51 (25–119) 86 (20–346) 0.135
Polymorphonuclears [median (IQR)] 10 (4–32) 14 (2–85) 0.684
Polymorphonuclear predominance 9 (31.0) 69 (46.0) 0.136
Lymphocytes [median (IQR)] 25 (3–68) 20 (6–88) 0.821
Lymphocyte predominance 20 (69.0) 81 (54.0) 0.136
Microbiological findings in CSF [n (%)]
Streptococcus pneumoniae 0 (0) 21 (14.0) 0.032
Herpes simplex virus 0 (0) 9 (6.0) 0.175
Enteroviruses 0 (0) 5 (3.3) 0.318
Mycobacterium tuberculosis 0 (0) 4 (2.6) 0.373
Varicella-zoster virus 0 (0) 4 (2.6) 0.373
Neisseria meningitidis 0 (0) 3 (2.0) 0.442
Haemophilus influenza 0 (0) 3 (2.0) 0.442
Listeria monocytogenes 0 (0) 3 (2.0) 0.442
Staphylococcus aureus 0 (0) 1 (0.7) 0.659
Propionibacterium acnes 0 (0) 1 (0.7) 0.659
Epstein barr 0 (0) 1 (0.7) 0.659
Streptococcus agalactiae 0 (0) 1 (0.7) 0.659
Influenza virus 0 (0) 1 (0.7) 0.659
Cryptococcus neoformans 0 (0) 1 (0.7) 0.659
Escherichia coli 0 (0) 1 (0.7) 0.659
All microbiological tests negative 29 (100) 91 (60.6) <0.001
SARS-CoV-2 RT-PCR result in CSF
Positive 1 (3.5) 0 (0) 0.022
Negative 9 (31.0) 15 (10) 0.002
Not done 19 (65.5) 135 (90) <0.001
Final etiological diagnosis of the ME
Bacterial 0 34 0.004
Tuberculosis 0 4 0.373
Viral (identified) 1 20 0.129
Unidentified (presumed bacterial) 9 (32.2) 28 (30.7) 0.890
Unidentified (presumed viral) 19 (67.8) 63 (69.3) 0.890
CSF, cerebrospinal fluid; ME, meningoencephalitis; IQR, interquartile range; RT_PCR, reverse transcriptase
polymerase chain reaction
p values in bold denote statistically significant differences (p<0.05)
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66.672) and admission to an ICU (OR=5.893;
95%CI=3.117–11.140), which were higher than in
COVID-non-ME patients (Fig. 2).
Discussion
ME is a life-threatening infection associated with substantial
mortality and a risk of permanent disability in survivors de-
spite the availability of highly active antibiotics and advances
in providing intensive care to critically ill patients [16]. The
ME syndrome is not usually observed as a form of COVID
presentation, but its incidence is higher than that observed for
non-COVID patients. We found that around 0.40‰ of
COVID patients in the ED had ME. While this incidence,
which was determined during a 2-month period of the
COVID pandemic, should be considered as low, it is more
than 4-fold higher than what is usually seen in non-COVID
patients. The epidemiology of ME is highly dependent on
geographical factors, the development of society, and the
number of preventive interventions, with an incidence of
0.6–4 cases per 100,000 adults/year in developed countries
[17, 18]. In the current report, and taking into account the
catchment area of the 61 EDs participating in the UMC-19-
S3 study (15.2 million inhabitants), the standardized incidence
of ME was 3.5 per 100,000 person/year (or 3.0 if we discount
ME cases observed in patients with COVID-19). Therefore,
these figures are close to those previously reported and rein-
force the reliability of the data presented in the UMC-
19-S3 study and suggest a direct role of SARS-CoV-2
infection in many of the cases of ME seen during the
COVID-19 pandemic.
The profile of patients with ME in COVID patients is not
different from that of ME observed in the general population
in terms of demographics and comorbidity. Neck stiffness was
less frequent in COVID-ME patients that in non-COVID-ME,
and there was a tendency to a lower frequency of Kernig’s and
Brudzinski’s signs.Within the context of a pandemic, this fact
may hamper the clinical diagnosis of ME and not overlook
any finding. The sensitivity of the classic triad of fever, neck
stiffness, and altered mental status is low (44%), but almost all
of these patients presented at least two out of the four symp-
toms—headache, fever, neck stiffness, and altered mental sta-
tus [19]. Headache, altered metal status, and fever are present
with the same frequency in COVID-ME and non-COVID-
ME. All of these symptoms must make physicians aware of
a possible diagnosis of ME even during the pandemic.
Actually, although COVID-19 preferentially affects the
Table 4 Magnitude of statistically significant associations found in the
unadjusted analysis
Odds ratio 95% confidence interval
Characteristics of meningoencephalitis in COVID patients (respect to
meningoencephalitis in non-COVID patients)
Ground-glass lung opacities 5.600 3.090–10.150
Interstitial lung infiltrates 5.369 2.901–9.937
Dyspnea 4.428 2.390–8.204
Neck stiffness 0.282 0.089–0.891
Risk factors in COVID patients to develop meningoencephalitis (respect
to COVID patients not developing meningoencephalitis)
Headache 24.727 10.165–60.149
Altered mental status 12.864 6.615–25.016
Neck stiffness 12.154 8.410–17.564
Vomiting 3.721 1.353–10.234
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respiratory system, neurological symptoms (such as headache,
dizziness, hypogeusia, and neuralgia) and complications (en-
cephalopathy, acute cerebrovascular diseases, impaired con-
sciousness, and skeletal muscular injury) have also been de-
scribed [1, 5, 20, 21]. Indeed, headache, altered metal status,
neck stiffness, and vomiting were associated with a higher risk
of ME in COVID patients. Nevertheless, the symptoms de-
scribed are commonplace in many severe infections and could
represent disturbances in neurological function rather than
neurological disease per se, and therefore, suspicion of ME
is important to begin the diagnostic process.
Coronaviruses are not primarily neurotropic virus, and their
primary target is the respiratory epithelium. The target recep-
tor for attachment to cells is through the angiotensin
converting enzyme-2 receptor (ACE 2). These receptors are
also found in glial cells in the brain and spinal neurons. Hence,
it can attach, multiply, and damage neuronal tissue. Some
mechanism of brain invasion has been postulated: (1) a retro-
grade transfer via the olfactory epithelium or through the crib-
riform bone; (2) disruption of the blood-brain barrier during
the viremia phase of illness causing the virus to enter the brain
directly; and (3) invasion of peripheral nerve terminals by
CoV which then gains entry to the CNS through the synapse
connected route [1, 5, 11, 20]. However, the mechanism by
which the CNS is affected is still unclear.
CSF detection of coronavirus RNA seems to be infrequent
[22, 23]. Although RT-PCR of CSF was negative/not per-
formed in the majority of patients, the CSF profiles compati-
ble with viral ME, the large screening for usual pathogens
with negative results, the temporal association with a
COVID diagnosis, and the knowledge that coronaviruses are
known for their neurological tropism for inducing encephalitis
suggest that SAR-CoV-2 could have been the pathogen re-
sponsible for the ME disease in several of our cases. In fact,
in one COVID-ME patient, the SARS-CoV-2 antigen was
detected in CSF by RT-PCR, demonstrating the invasive ca-
pacity of the virus. This is not unexpected, since over a num-
ber of years, human coronaviruses including SARS-CoV have
been identified as possible pathogens for pathologies outside
the respiratory systems [21, 24, 25]. One report showed that
SARS-CoV genome sequences were detected by RT-PCR in
brains of all SARS autopsies [26].
Several predictors of unfavorable outcome have been
described [27]: septic shock, seizures, advanced age,
low CSF glucose, low CSF leukocyte count and high
protein, systemic compromise, coma, pneumococcal
ethiology, high APACHE II score, cranial nerve paresis,
high erythrocyte sedimentation rate, absence of fever,
and longer interval to treatment. Among these, the more
frequent systemic compromise seen in COVID-ME pa-
tients could explain the increases in mortality. Case
group patients more frequently had dyspnea, chest X-
ray abnormalities, and higher acute-phase reactants.
Limitations
This study has several limitations. First, the diagnosis of
ME was based on clinical manifestations, lumbar punc-
ture, abnormality on electroencephalography, and CT
scan findings, and RT-PCR in CSF was not performed
in the majority of patients. However, as explained in the
“Discussion” section, a relationship between ME and
SARS-CoV-2 is plausible. Second, in about half of the
COVID patients with ME, SARS-CoV-2 infection was
not demonstrated by RT-PCR nasopharyngeal swab, and
diagnosis was based exclusively on clinical findings and
the presence of the typical lung parenchymal infiltrates
in chest X-ray or pulmonary CT. However, this has
been the case in many countries, due to the reagent
shortage experienced at the beginning of the pandemic
[28, 29]. Third, as the number of cases was not large,
we could not further investigate the significant relation-
ships identified in the unadjusted analysis by using ad-
justed models. However, ME is a very uncommon dis-
ease, and it is very difficult to add cases quickly
enough even in a national network to communicate the
results during the pandemic. Additionally, a type II er-
ror cannot be ruled out due to the limited sample size
of our series. Fourth, the retrospective nature of the
study could have led to a loss of cases and information
in the different sites. Although this information was
collected from the electronic databases of the EDs, a
possible selection bias cannot be ruled out, and it can-
not be ensured that all the possible cases in the different
hospitals were collected. Nonetheless, we believe that
the results reliably reflect the epidemiology and the
characteristics of ME during the COVID pandemic.
Conclusions
Despite these limitations, we conclude that the incidence
of ME in COVID patients attending the ED is low, at
about 0.4‰, but it is much higher than in the non-
COVID population. This suggests a potential role of
SARS-CoV-2 as an additional viral infection causative
of ME, which could be responsible for many of the lym-
phocytic ME cases seen during the pandemic. In fact, the
presence of the SARS-CoV-2 antigen was detected in the
CSF of one of the patients included in the UMC-19-S3.
Therefore, the presence of headache, altered mental status,
neck stiffness, and vomiting in COVID patients should be
a red flag for physicians evaluating COVID patients. The
ME-COVID group had an increased risk for in-hospital
mortality than non-COVID-ME.
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